Pacer Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Pacer Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-132	Closed	-$15K	–	2420
2022 Q4	$15K	Sell	132 -609,054	-100%	-$50.6M	﹤0.01%	3109
2022 Q3	$37.7M	Buy	+609,186	New	+$42.6M	0.26%	74
2016 Q3	–	Sell	-12,687	Closed	-$209K	–	1094
2016 Q2	$209K	Buy	+12,687	New	+$205K	0.03%	773

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Pacer Advisors's HZNP Position: Q1 2023 in Review

Pacer Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2023, closing a stake of 132 shares — an estimated $15K sold.

Pacer Advisors first reported a position in HZNP in Q2 2016 and held it in 3 quarters. The position peaked at $37.7M in Q3 2022. 553 funds tracked by Wall St. Rank hold HZNP as of Q1 2023.

Pacer Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Pacer Advisors sold 132 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2023, an estimated $15K.
Pacer Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2016 and held it in 3 quarters.
Pacer Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $37.7M in Q3 2022.
553 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2023.

Based on Pacer Advisors's 13F filing for Q1 2023, filed 2 May 2023.